학술논문
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Document Type
Article
Author
Source
In The Lancet Haematology June 2017 4(6):e272-e282
Subject
Language
ISSN
2352-3026